Search

Your search keyword '"Pela, G"' showing total 18 results
Start Over Author "Pela, G"
18 results on '"Pela, G"'

1. Treatment of Delirium in Older Persons: What We Should Not Do!

Author

Lauretani, F, Bellelli, G, Pela, G, Morganti, S, Tagliaferri, S, Maggio, M, Lauretani F., Bellelli G., Pela G., Morganti S., Tagliaferri S., Maggio M., Lauretani, F, Bellelli, G, Pela, G, Morganti, S, Tagliaferri, S, Maggio, M, Lauretani F., Bellelli G., Pela G., Morganti S., Tagliaferri S., and Maggio M.

Abstract

The presentation of common acute diseases in older age is often referred to as "atypical". Frequently, the symptoms are neither single nor tissue related. In most cases, the onset of symptoms and diseases is the expression of a diminished reserve with a failure of the body system and imbalance of brain function. Delirium is one of the main devastating and prevalent atypical symptoms and could be considered as a geriatric syndrome. It encompasses an array of neuropsychiatric symptoms and represents a disarrangement of the cerebral function in response to one or more stressors. The most recent definition, reported in the DSM-V, depicts delirium as a clear disturbance in attention and awareness. The deficit is to be developed in a relatively short time period (usually hours or days). The attention disorder must be associated with another cognitive impairment in memory, orientation, language, visual-spatial or perception abilities. For the treatment, it is imperative to remove the potential causes of delirium before prescribing drugs. Even a non-pharmacological approach to reducing the precipitating causes should be identified and planned. When we are forced to approach the pharmacological treatment of hyperactive delirium in older persons, we should select highly cost-effective drugs. High attention should be devoted to the correct balance between improvement of psychiatric symptoms and occurrence of side effects. Clinicians should be guided in the correct choice of drugs following cluster symptoms presentation, excluding drugs that could potentially produce complications rather than advantages. In this brief point-of-view, we propose a novel pharmacological flow-chart of treatment in relation to the basic clusters of diseases of an older patient acutely admitted to the hospital and, in particular, we emphasize "What We Should Not Do!", with the intention of avoiding possible side effects of drugs used.

Published
2020

2. PP.25.06

Author

Montanari, A., primary, Musiari, L., additional, Biggi, A., additional, Cabassi, A., additional, Crocamo, A., additional, Pela’, G., additional, and Cherney, D.Z., additional

Published
2015
Full Text
View/download PDF

3. PERTINENT - PERindopril-Thrombosis, InflammatioN, endothelial dysfunction and neurohormonal activation trial: A sub-study of the EUROPA study

Author

Ferrari, Roberto, Arbustini, E., Blann, A., Cokkinos, D., Kluft, C., de Maat, M. P. M., Tavazzi, L., Bertrand, R., Ferrari, R., Fox, K., Remme, W. J., Simoons, M. L., Christakos, S., Geleris, P., Gialafos, J., Kardaras, F., Karidis, K., Kelesides, C., Koliopolos, N., Pyrgakis, V., Stamatelopoulos, S., Stavridis, A., Syribeis, S., Vardas, P., Vassiliadis, J., Zacharoulis, A., Zobolos, S., Manolis, A., Giannetto, M., Azzolini, P., Bellone, E., Pela, G., Brunelli, C., Capponi, E., Casaccia, M., Ceci, V., Corsini, G., De Luca, I., De Servi, S., Guarnerio, M., Di Pasquale, G., Fiorentini, C., Giannuzzi, P., Giovannini, E., Sinagra, G. F., Pettinati, G., Polimeni, M. R., Santini, M., Tantalo, L., Vajola, S., Di Giacomo, U., Gaddi, O., Iacono, A., Riva, S., Cappucci, A., Marinoni, G. P., Inama, G., Antolini, R., Celegon, L., Sanguinetti, M., Cucchini, F., Renaldini, E., Giordano, A., Papi, S., Marzilli, M., Dalla Volta, S., Volterrani, M., Portaluppi, Francesco, Lorusso, R., Di Donato, M., Colombo, A., Branzi, A., Proto, C., Leghissa, R., Ferrera, R., Marques, A. L., Andrade, C. M. D., Urena, C. G., Salcedo, J. M. A., Garcia, P. A., Azcarate, J. A., Martinez, V. B., Coronado, J. L. B., Cortada, J. B., Barmejo, M. P., Calini, J. S. E., Horcajo, N. A., Guerrero, J. J. G., Lorente, J. L., Montero, J. M. M., Romero, P. M., Mayor, J. L. B., Lopez, F. N., Peiro, F. N., de Ros, J. O., Mas, J. O., Valderrama, J. C., Lopez, D. G., Sanz, A. S., Bonnin, S. J., Simarro, E., Belsue, F. V., Caimani, R. B., Aranda, V. L. G., Ligorit, A. D., Cocina, E. G., Miguel, C. M., and Sanpera, J. M. A.

Published
2003

4. [The short- and long-term results in heart surgery of the elderly]

Author

Pela G, Ferrari M, Raddino R, Caprini L, Marzollo P, Visioli O., ALFIERI , OTTAVIO, Pela, G, Ferrari, M, Raddino, R, Caprini, L, Marzollo, P, Alfieri, Ottavio, and Visioli, O.

Subjects
Male, Chi-Square Distribution, Time Factors, Survival Analysis, Postoperative Complications, Italy, Cause of Death, Quality of Life, Humans, Female, Cardiac Surgical Procedures, Aged, Follow-Up Studies, Retrospective Studies
Abstract

We have studied retrospectively 106 patients aged 69 years or older (range 69 to 79) who underwent cardiac surgery between November 1986 and December 1989. The majority of patients (61%) were male. Coronary artery bypass surgery was performed in 59 patients, isolated valve replacement in 38 and combined valve replacement with coronary artery bypass surgery in 5. Two patients underwent ascending aorta replacement for aortic dissection and 2 ventricular aneurysmectomy and postinfarction ventricular septal defect repair. The mean postoperative hospital stay was 12 days. Ninety-one percent of patients underwent a primary elective operation and 9% required an emergency operation. Hospital mortality was 5% (n = 6). All hospital survivors were followed up by telephone contact (mean follow-up: 37 months) to determine presence or absence of chest pain, dyspnea, postoperative NYHA class and the overall effect of surgery on quality of life. There were 16 follow-up deaths; 5 were non cardiac. Follow-up study showed significant improvement in symptom status and quality of life (96%). We concluded that cardiac surgery in the elderly, although associated with increased operative risk, gives excellent relief of symptoms and good survival.

Published
1992

11. [Pharmacologic characterization of the internal mammary artery used in myocardial revascularization]

Author

Raddino R, Gargano M, Pela G, Visioli O., ALFIERI , OTTAVIO, Raddino, R, Gargano, M, Pela, G, Alfieri, Ottavio, and Visioli, O.

Subjects
Adult, Male, Serotonin, Angiotensin II, Dopamine, Middle Aged, Acetylcholine, Potassium Chloride, Vasomotor System, Norepinephrine, Thoracic Arteries, Myocardial Revascularization, Humans, Mammary Arteries, Aged
Abstract

The aim of this study concerned the pharmacological investigation of the isolated internal mammary artery. Spirally-cut vascular segments were obtained from patients undergoing myocardial revascularization and set up in isolated baths under isometrical tension. Reactivity of internal mammary artery preparations to stimulatory and inhibitory agents was evaluated. KCl (90 mM), noradrenaline (10-8)-10(-5) M) and serotonine (10(-9)-10(-5) M) induced a tonic contraction lasting for more than 60 min. Angiotensin II (10(-6)-10(-5) M) and dopamine (10)-8)-10(4) M) resulted virtually uneffective. The serotonine-induced contractions were strongly inhibited by ketanserin (10-9)-10(-6) M), a selective S2-blocker, and also by verapamil (10(-3)-10(-6) M) and nitroglycerin (10(-7)-10(-5) M). These data suggest that internal mammary artery is sensitive to different contractile agents, in particular serotonine activates muscular contractions through S2 receptors. The knowledge of such a mechanism may be of clinical relevance.

Published
1989

13. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

Author

Fox, K. M., Bertrand, M., Ferrari, Roberto, Remme, W. J., Simoons, M. L., Simoons, M., Bassand, J. P., Aldershvile, J., Hildebrandt, P., Cokkinos, D., Toutouzas, P., Eha, J., Erhardt, L., Erikssen, J., Grybauskas, P., Kalnins, U., Karsch, K., Sechtem, U., Keltai, M., Klein, W., Luscher, T., Mulcahy, D., Nieminen, M., Oto, A., Ozsaruhan, O., Paulus, W., Providencia, L., Riecansky, I., Ruzyllo, W., Ferrari, R., Santini, U., Tavazzi, L., Soler Soler, J., Widimsky, P., Julian, D., Dargie, H., Murray, G., Kubler, W., Thygesen, K., Duprez, D., Steg, G., Drexel, H., Gombotz, G., Heyndrickx, G. H., Legrand, V., Materne, P., Van Mieghem, W., Bocek, P., Branny, M., Cech, M., Charouzek, J., Drazka, J., Fabik, L., Florian, J., Francek, L., Groch, L., Havranek, P., Hradec, J., Jansky, P., Jirmar, R., Jokl, I., Krejcova, H., Kvasnak, M., Maratka, T., Marcinek, G., Moravcova, J., Nedbal, P., Peterka, K., Povolny, J., Rosolova, H., Semrad, B., Sochor, K., Spacek, R., Spinar, J., Stipal, R., Stuchlik, K., Sulda, M., Ulman, J., Vaclavicek, A., Vojtisek, P., Bjerregaard Andersen, H., Kristensen, K., Madsen, J. K., Markenvard, J., Meibom, J., Norgaard, A., Scheibel, M., Leht, A., Teesalu, R., Vahula, V., Itkonen, A., Juvonen, J., Karmakoski, J., Kilkki, E., Koskela, E., Melin, J., Nieminen, M. S., Savola, R., Terho, T., Voipio Pulkki, L. M., Apffel, F., Attali, P., Barjhoux, C., Baron, B., Berthier, Y., Dambrine, P., Decoulx, E., Deshayes, P., Fouche, R., Genest, M., Godard, S., Guillot, J. P., Hanania, G., Khattar, P., Leroy, F., Mansourati, J., Piquemal, R., Quiret, J. C., Raynaud, P., Rondepierre, D., Roynard, J. L., Sudhibhasilp, S., Van Belle, E., Bilbal, A., Lauer, B., Rettig Sturmer, G., Riessen, R., Rutsch, W., Sigel, H. A., Simon, R., Von Schacky, C., Winkelmann, B. R., Avgeropoulou, C., Christakos, S., Feggos, S., Floros, S., Fotiadis, I., Goudevenos, I., Kardara, D., Karidis, C., Koliopoulos, N., Kremastinos, D., Lekakis, I., Manolis, A., Pyrgakis, V., Papanikolaou, C., Papasteriadis, E., Skoufas, P., Stravrati, A., Stavridis, A., Syribeis, S., Vardas, P., Vassiliadis, I., Voudris, V., Zobolos, S., Berenyi, I., Edes, I., Janosi, A., Kalo, E., Karpati, P., Kornel, S., Pap, I., Polak, G., Reiber, I., Rusznak, M., Tarjan, J., Timar, S., Toth, K., Barton, J., Crean, P., Daly, K., Kearney, P., Meany, T. B., Quigley, P., Antolini, R., Azzolini, P., Bellone, E., Branzi, A., Brunelli, C., Capponi, E., Capucci, A., Casaccia, M., Cecchetti, E., Ceci, V., Celegon, L., Colombo, A., Corsini, G., Cucchini, F., Dalla Volta, S., De Caterina, R., De Luca, I., De Servi, S., Di Donato, M., Di Giacomo, U., Di Pasquale, G., Fiorentini, C., Gaddi, O., Giannetto, M., Giannuzzi, P., Giordano, A., Giovannini, E., Guarnierio, M., Iacono, A., Inama, G., Leghissa, R., Lorusso, R., Marinoni, G., Marzilli, M., Mauri, F., Mosele, G. M., Papi, S., Pela, G., Pettinati, G., Polimeni, M. R., Portaluppi, Francesco, Proto, C., Renaldini, E., Riva, S., Sanguinetti, M., Santini, M., Severi, S., Sinagra, G., Tantalo, L., Vajola, S. F., Volterrani, M., Ansmite, B., Gailiss, E., Gersamija, A., Ozolina, M. A., Baubiniene, A., Berukstis, E., Grigoniene, L., Kibarskis, A., Kirkutis, A., Marcinkus, R., Milvidaite, I., Vasiliauskas, D., Aalders, J. C. A., Bruggeling, W. A. J., De Feyter, P. J., De Leeuw, M. J., De Waard, D. E. P., De Weerd, G. J., De Zwaan, C., Dijkgraaf, R., Droste, H. T., Freericks, M. P., Hagoort Kok, A. W., Hillebrand, F., Jap, W. T. J., Jochemsen, G. M., Kiemeney, F., Kuijer, P. J. P., Mannaerts, H. F. J., Piek, J. J., Saelman, J. P. M., Slob, F. D., Smits, W. C. G., Suttorp, M. J., Tan, T. B., Van Beek, G. J., Van den Merkhof, L. F. M., Van der Heyden, R., Van Hessen, M. W. J., Van Langeveld, R. A. M., Van Nierop, P. R., Van Rey, F. J. W., Van Straalen, M. J., Vos, J., Werner, H. A., Westendorp, J. J. C., Achremczyk, P., Adamus, J., Baska, J., Bolinska Soltysiak, H., Bubinski, R., Ceremuzynski, L., Cieslinski, A., Dariusz, D., Drozdowski, P., Dubiel, J. S., Galewicz, M., Halawa, B., Janion, M., Jaworska, K., Kaszewska, I., Kleinrok, A., Kornacewicz Jach, Z., Krawczyk, W., Krynicki, R., Krzciuk, M., Krzeminska Pakula, M., Kuch, J., Kuzniar, J., Liszewska Pfejfer, D., Loboz Grudzien, K., Musial, W., Opolski, G., Pasyk, S., Piwowarska, W., Pulkowski, G., Rynkiewicz, A., Sinkiewicz, W., Skura, M., Slowinski, S., Smielak Korombel, W., Targonski, R., Templin, W., Tendera, M., Tracz, W., Trusz Gluza, M., Wodniecki, J., Zalewski, M., Zinka, E., Carrageta, M., Gil, J. C., Ferreira, R., Marques, A. L., Andrade, C. M. S., Seabra Gomes, R., Bada, V., Belicova, M., Dukat, A., Kaliska, G., Kamensky, G., Micko, K., Mikes, Z., Palinsky, M., Pella, D., Renker, B., Sefara, P., Sojka, G., Sulej, P., Szakacs, M., Salcedo, J. M. A., Orcajo, N. A., Garcia, P. A., Sanpera, J. M. A., Azcarate, J. A., Mayor, J. L. B., Martinez, V. B., Coronado, J. L. B., Ojeda, F. B., Caimari, R. B., Cortada, J. B., Valderrama, J. C., Ligorit, A. D., Caliani, J. S. E., Aviles, F. F., Guerrero, J. J. G., Lopez, D. G., Cocina, E. G., Urena, C. G., Lorente, L. J., Garcia Aranda, V. L., De Miguel, C. M., Montero, J. M., Romero, P. M., Benito, I. M., Lopez, F. N., Peiro, F. N., De Ros, J. O., Mas, J. O., Bermejo, M. A. P., Peralta, L. J. P., Padial, L. R., Sanz, A. S., Bonnin, J. S., Martin, E. S., Belsue, F. V., Ekdahl, S., Forslund, L., Ohlin, H., Pieper, M., Moccetti, T., Acarturk, E., Guzelsoy, D., Turkoglu, C., Adgey, A. A. J., Ahsan, A., Al Khafaji, M., Ball, S. G., Birkhead, J., Boon, N., Brack, M., Bridges, A., Buchalter, M., Calder, B., Cooke, R. A., Corr, L., Cowell, R., Curzen, N. P., Davidson, C., Davies, J., De Belder, M. A., Dhiya, L., Doig, J. C., Findlay, I. N., Francis, C. M., Glancy, J. M., Greenwood, T. W., Groves, P., Hall, A. S., Hamilton, G., Haq, I., Hillman, R., Hubbard, W., Hudson, I., Hutton, I., Ilsley, C., Innes, M., James, M., Jennings, K., Johnston, G., Jones, C. J. H., Joy, M., Keeling, P., Kooner, J., Lawson, C., Levy, R. D., Lip, G., Mclachlan, B., Montgomery, H. E., Morley, C. A., Murdoch, D. L., Muthusamy, R., Oakley, G. D. G., Penny, W., Percival, R., Purvis, J., Pye, M. P., Ramsdale, D., Roberts, D. H., Rozkovec, A., Salmassi, A. M., Saltissi, S., Sardar, S., Shapiro, L. M., Schofield, P. M., Stephens, J., Shakespeare, C., Srivastava, S., Swan, J. W., Tildesley, G., Travill, C., Wilkinson, P. R., Fratacci, M. D., Lerebours, G., and Deckers, J.

Subjects
Relative risk reduction, Male, medicine.medical_specialty, Myocardial Infarction, Angiotensin-Converting Enzyme Inhibitors, Coronary Disease, Coronary artery disease, Double-Blind Method, Internal medicine, Cause of Death, Clinical endpoint, Perindopril, Medicine, Humans, Myocardial infarction, Heart Failure, Ejection fraction, business.industry, General Medicine, Middle Aged, medicine.disease, Heart Arrest, Treatment Outcome, Cardiovascular Diseases, Heart failure, ACE inhibitor, Cardiology, Female, business, circulatory and respiratory physiology, medicine.drug, Follow-Up Studies
Abstract

Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.

15. Treatment of Delirium in Older Persons: What We Should Not Do!

Author

Giovanna Pelà, Sara Tagliaferri, Giuseppe Bellelli, Marcello Maggio, Fulvio Lauretani, S. Morganti, Lauretani, F, Bellelli, G, Pela, G, Morganti, S, Tagliaferri, S, and Maggio, M

Subjects
medicine.medical_specialty, media_common.quotation_subject, Review, Catalysis, Pharmacological treatment, Inorganic Chemistry, lcsh:Chemistry, 03 medical and health sciences, 0302 clinical medicine, delirium, pharmacological treatment, Orientation (mental), Perception, Cerebral function, Medicine, Humans, Cognitive Dysfunction, 030212 general & internal medicine, Physical and Theoretical Chemistry, Intensive care medicine, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, Brain function, media_common, Balance (ability), older person, Psychotropic Drugs, business.industry, Organic Chemistry, Stressor, General Medicine, Computer Science Applications, Hospitalization, neurogeriatric disorders, lcsh:Biology (General), lcsh:QD1-999, Acute Disease, older persons, Delirium, neurogeriatric disorder, medicine.symptom, business, Cognition Disorders, 030217 neurology & neurosurgery
Abstract

The presentation of common acute diseases in older age is often referred to as “atypical”. Frequently, the symptoms are neither single nor tissue related. In most cases, the onset of symptoms and diseases is the expression of a diminished reserve with a failure of the body system and imbalance of brain function. Delirium is one of the main devastating and prevalent atypical symptoms and could be considered as a geriatric syndrome. It encompasses an array of neuropsychiatric symptoms and represents a disarrangement of the cerebral function in response to one or more stressors. The most recent definition, reported in the DSM-V, depicts delirium as a clear disturbance in attention and awareness. The deficit is to be developed in a relatively short time period (usually hours or days). The attention disorder must be associated with another cognitive impairment in memory, orientation, language, visual-spatial or perception abilities. For the treatment, it is imperative to remove the potential causes of delirium before prescribing drugs. Even a non-pharmacological approach to reducing the precipitating causes should be identified and planned. When we are forced to approach the pharmacological treatment of hyperactive delirium in older persons, we should select highly cost-effective drugs. High attention should be devoted to the correct balance between improvement of psychiatric symptoms and occurrence of side effects. Clinicians should be guided in the correct choice of drugs following cluster symptoms presentation, excluding drugs that could potentially produce complications rather than advantages. In this brief point-of-view, we propose a novel pharmacological flow-chart of treatment in relation to the basic clusters of diseases of an older patient acutely admitted to the hospital and, in particular, we emphasize “What We Should Not Do!”, with the intention of avoiding possible side effects of drugs used.

Published
2020

16. Long-term changes in left ventricular mass, chamber size and function after valve replacement in patients with severe aortic stenosis and depressed ejection fraction

Author

Giovanna Pelà, Ottavio Alfieri, Marco Metra, Odoardo Visioli, Claudio Ceconi, G. La Canna, P Berra Centurini, Pela, G, La Canna, G, Metra, M, Ceconi, C, Berra Centurini, P, Alfieri, Ottavio, and Visioli, O.

Subjects
Aortic valve, Male, Time Factors, medicine.medical_treatment, Left, Hemodynamics, Ventricular Dysfunction, Left, Valve replacement, Aortic valve replacement, 80 and over, Ventricular Dysfunction, Pharmacology (medical), Aged, Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, complications/surgery/ultrasonography, Echocardiography, Doppler, Exercise Test, Female, Follow-Up Studies, Heart Valve Prosthesis, Heart Ventricles, physiopathology/ultrasonography, Humans, Hypertrophy, Left Ventricular, complications/physiopathology/ultrasonography, Male, Middle Aged, Prognosis, Retrospective Studies, Stroke Volume, physiology, Time Factors, Ventricular Dysfunction, etiology/physiopathology/ultrasonography, Aged, 80 and over, Ejection fraction, medicine.diagnostic_test, physiopathology/ultrasonography, Doppler, Middle Aged, Prognosis, Echocardiography, Doppler, medicine.anatomical_structure, Echocardiography, Aortic Valve, Heart Valve Prosthesis, Cardiology, Ventricular pressure, Hypertrophy, Left Ventricular, Female, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Heart Ventricles, Physical examination, Internal medicine, medicine, Humans, Aged, Retrospective Studies, business.industry, complications/surgery/ultrasonography, Stroke Volume, Aortic Valve Stenosis, Hypertrophy, medicine.disease, Surgery, Stenosis, physiology, Exercise Test, complications/physiopathology/ultrasonography, business, Follow-Up Studies
Abstract

We studied 21 patients undergoing valve replacement for severe aortic stenosis and marked left ventricular dysfunction (mean ejection fraction 27 +/- 7.9%) without significant coronary disease or other valve diseases. At 5-60 months (average 26 +/- 18) after surgery, the patients underwent a clinical history, physical examination and a complete M-mode, two-dimensional and Doppler transthoracic echocardiographic study. Thirteen patients were examined with cardiopulmonary exercise testing. Two patients with a low preoperative transvalvular pressure gradient (

Published
1997

17. [Anti-arrhythmic action of magnesium sulfate in "torsade de pointes" ventricular arrhythmia].

Author

Bolognesi R, Tsialtas D, Cortesi G, Pela G, and Manca C

Subjects
Aged, Electrocardiography, Female, Humans, Magnesium Sulfate therapeutic use, Tachycardia drug therapy
Abstract

A female patient with recurrent "torsades de pointes" and a long QT interval was successfully treated with i.v. magnesium sulfate. This work provides further support of the use of magnesium sulfate in this particular arrhythmia.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results